4D Molecular Therapeutics
FDMT
147 hedge funds and large institutions have $1.79B invested in 4D Molecular Therapeutics in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 48 increasing their positions, 38 reducing their positions, and 18 closing their positions.
345% more capital inflows, than outflows
Capital inflows: $464M | Capital outflows: $104M
200% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
87% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $13.2M
32.55% more ownership
Funds ownership: 99.26% → 131.81% (+33%)
32% more funds holding
Funds holding: 111 → 147 (+36)
26% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$57.2M |
| 2 |
Polar Capital Holdings
London,
United Kingdom
|
+$45.9M |
| 3 |
Redmile Group
San Francisco,
California
|
+$32.2M |
| 4 |
Braidwell
Stamford,
Connecticut
|
+$26.9M |
| 5 |
VR Adviser
New York
|
+$24.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$47.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.32M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.43M |
| 4 |
Casdin Capital
New York
|
-$5.97M |
| 5 |
Integral Health Asset Management
New York
|
-$3.19M |
FDMT Hedge Fund Activity: Q1 2024 in Review
147 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2024, worth a combined $1.79B — up 109% from $860M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new FDMT positions and 18 closed out — a net gain of 36 holders — while 48 added to existing stakes and 38 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $57.2M. The largest seller was Viking Global Investors, cutting an estimated $47.3M.
- 147 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2024, up from 111 in Q4 2023.
- Funds reported $1.79B of 4D Molecular Therapeutics stock for Q1 2024, up 109% quarter-over-quarter.
- 54 funds opened new 4D Molecular Therapeutics positions in Q1 2024 and 18 closed out, a net change of +36 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2024 was Goldman Sachs, an estimated $57.2M added.
- The largest 4D Molecular Therapeutics seller in Q1 2024 was Viking Global Investors, an estimated $47.3M sold.
Based on aggregated 13F filings for Q1 2024.